Canadian Cancer Trials Group Bulletins

Trial Management Group

BL12 Closed to Accrual

The CCTG led BL12 study, has met its target accrual, with a total of 199 patients from Australia and Canada participating over 3 years.

The accrual target was achieved within the timelines outlined in the protocol and we estimate that all patients will have completed protocol therapy in approximately 4 - 5 months.

The BL12 study is a Multicentre Randomized Phase II Trial Comparing Nab-Paclitaxel to Paclitaxel in Patients with Advanced Urothelial Cancer Progressing on or after a Platinum Containing Regimen.

Primary Objective:
Progression free survival(PFS).

Secondary Objectives:
Objective response rates (ORR), clinical benefit rate (CBR), time to response and response duration, safety, QOL, and health analysis.

Exploratory Objectives:
Correlative Biology, Health and Demographic Assessment.

For more information please contact the study coordinator: Gail McDonald.